On December 16, 2021, Metrion Biosciences Limited, the specialist ion channel contract research and drug discovery company, and Bioqube Ventures, a specialist European life sciences investment firm, announced that they have entered into a collaboration, backed by Bioqube Factory Fund I, to incubate a drug discovery research project targeting autoimmune diseases. Under terms of the collaboration, Bioqube and Metrion will advance a lead series of previously identified highly potent and selective small molecule inhibitors of the human Kv1.3 potassium ion channel to enable further development. Activation of this voltage-gated ion channel in effector memory T-cells is thought to be an early and necessary step in the development of auto-immune diseases, including rheumatoid arthritis, lupus nephritis, psoriasis, multiple sclerosis, and many others. The lead candidate(s) will then be progressed for further development and human clinical trials.
Login Or Register To Read Full Story